At the end of past century, when the prevailing view was that treatment of autoimmunity required immune suppression, experimental evidence suggested an approach of immune-stimulation such as with the BCG vaccine in type 1 diabetes (T1D) and multiple sclerosis (MS). Translating these basic studies into clinical trials, we showed the following: BCG harnessed the immune system to 'permanently' lower blood sugar, even in advanced T1D; BCG appeared to delay the disease progression in early MS; the effects were long-lasting (years after vaccination) in both diseases. The recently demonstrated capacity of BCG to boost glycolysis may explain both the improvement of metabolic indexes in T1D, and the more efficient generation of inducible regulatory T cells, which counteract the autoimmune attack and foster repair mechanisms.

Bridging the gap between vaccination with Bacille Calmette-Guérin (BCG) and immunological tolerance: the cases of type 1 diabetes and multiple sclerosis / Ristori, Giovanni; Faustman, Denise; Matarese, Giuseppe; Romano, Silvia; Salvetti, Marco. - In: CURRENT OPINION IN IMMUNOLOGY. - ISSN 0952-7915. - 55:(2018), pp. 89-96. [10.1016/j.coi.2018.09.016]

Bridging the gap between vaccination with Bacille Calmette-Guérin (BCG) and immunological tolerance: the cases of type 1 diabetes and multiple sclerosis

Ristori, Giovanni;Matarese, Giuseppe;Romano, Silvia;Salvetti, Marco
2018

Abstract

At the end of past century, when the prevailing view was that treatment of autoimmunity required immune suppression, experimental evidence suggested an approach of immune-stimulation such as with the BCG vaccine in type 1 diabetes (T1D) and multiple sclerosis (MS). Translating these basic studies into clinical trials, we showed the following: BCG harnessed the immune system to 'permanently' lower blood sugar, even in advanced T1D; BCG appeared to delay the disease progression in early MS; the effects were long-lasting (years after vaccination) in both diseases. The recently demonstrated capacity of BCG to boost glycolysis may explain both the improvement of metabolic indexes in T1D, and the more efficient generation of inducible regulatory T cells, which counteract the autoimmune attack and foster repair mechanisms.
2018
BCG vaccine; type 1 diabetes; multiple sclerosis (MS)
01 Pubblicazione su rivista::01a Articolo in rivista
Bridging the gap between vaccination with Bacille Calmette-Guérin (BCG) and immunological tolerance: the cases of type 1 diabetes and multiple sclerosis / Ristori, Giovanni; Faustman, Denise; Matarese, Giuseppe; Romano, Silvia; Salvetti, Marco. - In: CURRENT OPINION IN IMMUNOLOGY. - ISSN 0952-7915. - 55:(2018), pp. 89-96. [10.1016/j.coi.2018.09.016]
File allegati a questo prodotto
File Dimensione Formato  
Ristori_Bridging_2018.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 1.11 MB
Formato Adobe PDF
1.11 MB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1195401
Citazioni
  • ???jsp.display-item.citation.pmc??? 13
  • Scopus 37
  • ???jsp.display-item.citation.isi??? 38
social impact